Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis

• Market Cap: ¥7.83B
• Dividend Yield: N/A
• Average Volume (3M): 42.12K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.89
• Revenue Growth: -17.95%
• EPS Growth: N/A
• Country: JP
• Employees: 229
• Sector: Consumer Defensive
• Sector Strength: 55
• Industry: Household & Personal Products
• EPS (TTM): 20.82
• Shares Outstanding: 8,720,534
• 10 Day Avg. Volume: 24,930
• 30 Day Avg. Volume: 42,123
• PEG Ratio: 0.08
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ¥1,049.00 ▲(17.87%Upside)

The overall stock score reflects strong technical momentum, despite financial performance challenges. The stable valuation supports the stock's appeal, although improving revenue and cash flow remain critical for future growth.

Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model

Company Description

Premier Anti-Aging Co., Ltd. (4934) is a Japanese company specializing in the development, manufacturing, and marketing of skincare and cosmetic products. The company is renowned for its focus on anti-aging solutions, leveraging advanced technologies and innovative ingredients to deliver high-quality products. Its product portfolio includes a wide range of skincare items such as creams, serums, and lotions, all aimed at helping consumers maintain youthful and healthy skin.

How the Company Makes Money

Premier Anti-Aging Co., Ltd. generates revenue primarily through the sale of its skincare and cosmetic products. The company distributes its products both domestically and internationally, utilizing various sales channels, including direct sales, retail partnerships, and e-commerce platforms. Key revenue streams include direct consumer sales through online platforms and collaborations with retail partners to reach a broader audience. Additionally, the company may engage in strategic marketing and branding efforts to enhance product visibility and appeal. Partnerships with distributors and retailers are significant factors that contribute to the company's earnings by expanding its market presence and accessibility.

Premier Anti-Aging Co., Ltd. Financial Statement Overview

Summary

Premier Anti-Aging Co., Ltd. is experiencing financial challenges with declining revenue and profitability. While the balance sheet remains relatively stable, cash flow issues are concerning and need to be addressed for improved financial health.

Income Statement

The income statement reveals a concerning trend of declining revenue and profitability. The gross profit margin has remained high, but net profit margin has been negative for recent years, with 2024 showing significant net losses. Revenue has decreased consistently since 2022, indicating problematic revenue growth and operational challenges.

Balance Sheet

The balance sheet is relatively stable, with a steady stockholders' equity and manageable debt levels. The debt-to-equity ratio remains reasonable, and the equity ratio is healthy, indicating a solid capital structure. However, declining total assets could pose a risk if the trend continues.

Cash Flow

Cash flow analysis shows fluctuating free cash flow, with recent periods experiencing negative figures. Operating cash flow has been positive, but the lack of consistent free cash flow growth is a concern. The company needs to improve cash flow management to ensure financial stability.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	19.32B	20.36B	26.40B	33.91B	32.81B	20.51B
Gross Profit	15.33B	16.10B	19.24B	26.63B	26.43B	16.48B
EBITDA	16.50M	-627.00M	-432.24M	2.67B	4.71B	1.68B
Net Income	-1.03B	-1.48B	-733.97M	1.42B	2.79B	1.14B
Balance Sheet
Total Assets	11.16B	11.00B	12.14B	12.30B	13.07B	6.85B
Cash, Cash Equivalents and Short-Term Investments	5.06B	4.76B	4.67B	2.97B	6.06B	1.90B
Total Debt	2.06B	2.44B	2.26B	1.41B	911.41M	1.99B
Total Liabilities	4.63B	4.88B	4.53B	3.95B	6.17B	5.40B
Stockholders Equity	6.54B	6.12B	7.61B	8.35B	6.90B	1.45B
Cash Flow
Free Cash Flow	0.00	-395.00M	1.64B	-3.53B	2.68B	196.34M
Operating Cash Flow	0.00	425.00M	2.42B	-3.32B	2.75B	338.23M
Investing Cash Flow	0.00	-540.00M	-900.97M	-297.68M	-180.83M	-135.76M
Financing Cash Flow	0.00	183.00M	179.77M	501.62M	1.58B	979.68M

Premier Anti-Aging Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 890.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Positive. The current price of 890 is below the 20-day moving average (MA) of 922.20, below the 50-day MA of 893.54, and above the 200-day MA of 808.01, indicating a bullish trend. The MACD of 5.12 indicates Positive momentum. The RSI at 60.50 is Neutral, neither overbought nor oversold. The STOCH value of 53.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4934.

Premier Anti-Aging Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4936	69 Neutral	¥11.43B	55.71		2.11%	4.75%	-83.63%
4934	69 Neutral	¥7.83B	10.65		―	-17.95%	―
Sector *	68 Neutral	€7.72B	15.81	12.45%	2.53%	2.04%	4.27%
4935	62 Neutral	¥9.57B	10,315.80		0.57%	16.15%	19.02%
4925	61 Neutral	¥6.19B	10.74		2.44%	-2.13%	―
4929	52 Neutral	¥7.22B	176.82		1.33%	-7.66%	―
4926	45 Neutral	¥4.82B	35.38		1.78%	0.10%	-239.09%

Premier Anti-Aging Co., Ltd. Corporate Events

Premier Anti-Aging Revises Earnings Forecast Amid Mixed Business Performance

Premier Anti-Aging Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending July 31, 2025, due to mixed performance across its business segments. While the recovery business through subsidiary Venex Co., Ltd. showed strong sales, the anti-aging segment underperformed, leading to an overall reduction in expected net sales. Despite this, operating profit exceeded expectations due to reduced advertising expenses and effective cost management. The company plans to invest in marketing for its renewed ‘DUO’ brand and new ‘Lalaskin’ skincare line, while remaining cautious about the challenging business environment, particularly in the Chinese market.

Premier Anti-Aging Reports Financial Results and Revises Forecasts

Premier Anti-Aging Co., Ltd. reported a decrease in net sales and operating profits for the first nine months of the fiscal year ending July 31, 2025, compared to the previous year. Despite the decline in sales, the company achieved a profit attributable to owners of the parent, indicating a recovery from the previous year’s losses. The company has revised its earnings forecasts for the full fiscal year, suggesting a cautious yet optimistic outlook for future performance.